Menu

MecMeth/NOA-24 trial

Mecmeth

Phase I/II trial of meclofenamate (MFA) in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy 

Objectives and endpoints

In the phase I component, the primary objective is to determine the toxicity of meclofenamate (MFA) therapy in addition to standard temozolomide (TMZ) in patients with the first relapse of MGMT promotor methylated glioblastoma. Efficacy, safety, tolerability and impact on quality of life are the secondary objectives. In phase II, the main objective is to determine the efficacy of MFA in addition to TMZ therapy.  The primary endpoint in phase I is the incidence of dose-limiting toxicities (DLTs) during the first 8 weeks of MFA treatment. In phase II,  the primary endpoint is progression-free survival (PFS) determined according to RANO criteria in cranial MRI.

Trial design

The study consists of a single-arm phase I part with 10 German trial sites and a randomized, parallel-group, and blinded phase II part with 15 German trial sites.  

Inclusion criteria

  1. First relapse after first-line therapy with radiotherapy (RT) and alkylating chemotherapy, > 3 months after last chemotherapy application and >6 months after end of RT. Drug therapy and/or radiotherapy for  first relapse treatment not yet started
  2. Tumor progression according to response-assessment in neurooncology (RANO) criteria
  3. Written informed consent 
  4. Cognitive state to understand rationale and necessity of study therapy and procedures 
  5. MGMT promotor-methylated, isocitrate-dehydrogenase (IDH) wildtype glioblastoma or gliosarcoma confirmed with histology of the primary resection 
  6. Age > 18 years
  7. Karnofsky performance score (KPS) ≥ 60%;
  8. Life expectancy > 6 months
  9. Adequate bone marrow reserve (white blood cell count (WBC) >3 G/nl, platelets >100 G/nl) 
  10. Adequate liver function (bilirubin <1.5 x upper limit of normal (ULN); ASAT /ALAT <3 x ULN, creatinine < 1.5 x ULN) 
  11. Patient compliance and geographic proximity that allow adequate follow-up
  12. Male and female patients with reproductive potential must use an approved contraceptive method during and for 3 months after the trial (Pearl index <1%)
  13. Pre-menopausal female patients with childbearing potential: a negative serum pregnancy test (beta-HCG) must be obtained prior to treatment start​

Additional criterion for phase I: 

  1. Resection at first relapse not yet performed; according to the local treating neurosurgeon and the documented decision of local neurooncological tumor board, re-resection of the tumor is clinically indicated and can be safely deferred until day 7-10 after initiation of MFA/TMZ therapy.

Study protocol

Mecmeth Phase1

In phase I, there is one treatment arm with 6-12 patients. A dose-finding algorithm for MFA is performed. Patients are pretreated with MFA in addition to standard TMZ and tumor resection will be performed 7-10 days after therapy initiation. Postoperatively, TMZ is administered for eight 28-day cycles with daily MFA therapy. 
Phase II will randomize 60 patients into an experimental treatment arm with MFA (dose determined in phase I) in addition to standard TMZ and the standard treatment arm with TMZ monotherapy. With 30 subjects per arm and a two-sided alpha level of 10%, this sample size provides a power of 80% at a hazard ratio of approximately 0.44, if a PFS-6 of 40% for the reference treatment is assumed.​ The trial is monitored by a Data Safety Monitoring Board. Modified from Zeyen et al., Trials, 2021

Study protocol

Accompanying scientific program

As patients are pretreated with MFA 7-10 days prior to surgery in the phase I component, the resected tumor material provides the opportunity to perform MFA tissue level measurements and investigate the extent of blood-brain barrier permeability of MFA. Phase I and II will enable comprehensive morphological and transcriptional tumor network analysis and therefore provide human in-vivo insights into the cellular dynamics of a therapy that might target tumor microtube-based network connectivity. 

Recruitment

Recruitment Mecmeth

Initiation of the trial: April 2022
Number of patients included: 6
​(Effective: 17 Feb 2024)

Funding

 
Unsere Webseite verwendet Cookies.

Bei Cookies handelt es sich um Textdateien, die im Internetbrowser bzw. vom Internetbrowser auf dem Computersystem des Nutzers gespeichert werden. Ruft ein Nutzer eine Website auf, so kann ein Cookie auf dem Betriebssystem des Nutzers gespeichert werden. Dieser Cookie enthält eine charakteristische Zeichenfolge, die eine eindeutige Identifizierung des Browsers beim erneuten Aufrufen der Website ermöglicht. Wir setzen Cookies ein, um unsere Website nutzerfreundlicher zu gestalten. Einige Elemente unserer Internetseite erfordern es, dass der aufrufende Browser auch nach einem Seitenwechsel identifiziert werden kann.

Unsere Webseite verwendet Cookies.

Bei Cookies handelt es sich um Textdateien, die im Internetbrowser bzw. vom Internetbrowser auf dem Computersystem des Nutzers gespeichert werden. Ruft ein Nutzer eine Website auf, so kann ein Cookie auf dem Betriebssystem des Nutzers gespeichert werden. Dieser Cookie enthält eine charakteristische Zeichenfolge, die eine eindeutige Identifizierung des Browsers beim erneuten Aufrufen der Website ermöglicht. Wir setzen Cookies ein, um unsere Website nutzerfreundlicher zu gestalten. Einige Elemente unserer Internetseite erfordern es, dass der aufrufende Browser auch nach einem Seitenwechsel identifiziert werden kann.

Ihre Cookie-Einstellungen wurden gespeichert.